| |||||||
Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Background Strain NOD/ShiLt Donor Strain 129S4/SvJae and 129P2/OlaHsd (via C57BL/6) H2 Haplotype g7 Generation N1F5p Appearance
albino
Related Genotype: A/A Tyrc/TyrcDevelopment
This triple mutant was created by intercrossing NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/Lt and NOD.129P2(B6)-Cd38tm1Lnd/LtJ (Stock No. 004311). F1 mice were backcrossed to NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/Lt to generate mice homozygous for the Art2a and Art2b alleles and heterozygous for Cd38tm1Lnd. Subsequent matings generated the triple homozygous mutant.
| Control | ||
|---|---|---|
| 001976 NOD/ShiLtJ | ||
| Considerations for Choosing Controls | ||
Strains carrying Art2atm1Fkn allele
004307 NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/Lt 008252 NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/LtJ View Strains carrying Art2atm1Fkn (2 strains)
Strains carrying Art2btm1Fkn allele
004307 NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/Lt 008252 NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/LtJ View Strains carrying Art2btm1Fkn (2 strains)
Strains carrying Cd38tm1Lnd allele
003727 B6.129P2-Cd38tm1Lnd/J 004311 NOD.129P2(B6)-Cd38tm1Lnd/LtJ 005345 NOD.Cg-Cd38tm1Lnd Prkdcscid/LtJ View Strains carrying Cd38tm1Lnd (3 strains)
Congenic Nomenclature
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Art2atm1Fkn/Art2atm1Fkn Art2btm1Fkn/Art2btm1Fkn Cd38tm1Lnd/Cd38tm1Lnd
NOD.129(B6)-Cd38tm1Lnd Art2atm1Fkn Art2btm1Fkn/Lt
- immune system phenotype
- decreased susceptibility to autoimmune diabetes (MGI Ref ID J:108097)
- double knockout NOD mice exhibit strong protection from diabetes in both sexes; female knockouts acquire diabetes at a frequency of 25% by 28 weeks compared to 100% in Cd38-null NOD females; double knockout NOD males are completely protected at 28 weeks compared to 100% incidence in Cd38-null NOD males
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Cd38tm1Lnd relatedDiabetes and Obesity Research
Type 1 Diabetes (IDDM)
Cancer Research
Genes Regulating Growth and Proliferation
Diabetes and Obesity Research
Type 1 Diabetes (IDDM)
Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Inflammation
| Allele Symbol | Art2atm1Fkn | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Friedrich Koch-Noltet | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | ART2.1-; | ||
| Strain of Origin | 129S4/SvJae | ||
| ES Cell Line Name | J1 | ||
| ES Cell Line Strain | 129S4/SvJae | ||
| Gene Symbol and Name | Art2a, ADP-ribosyltransferase 2a | ||
| Chromosome | 7 | ||
| Gene Common Name(s) | ART1P; Ly92a; RT6; Rt-6; Rt6; Rt6-1; rat homolog Rt6, locus 1; rat homolog of transplantable antigen gene RT6; | ||
| General Note |
Successfully targeted ES cells were subsequently targeted with the construct for the Art2b | ||
| Molecular Note | The coding region was disrupted by a neomycin selection cassette inserted by homologous recombination. ES cell were then transfected with the Art2btm1Fkn construct. Transcript was undetected in homozygous mutant mice by RT-PCR analysis of T cells isolated from lymph nodes. [MGI Ref ID J:79607] | ||
| Allele Symbol | Art2btm1Fkn | ||
| Allele Name | targeted mutation 1, Friedrich Koch-Nolte | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | ART2.2-; | ||
| Strain of Origin | 129S4/SvJae | ||
| ES Cell Line Name | J1 | ||
| ES Cell Line Strain | 129S4/SvJae | ||
| Gene Symbol and Name | Art2b, ADP-ribosyltransferase 2b | ||
| Chromosome | 7 | ||
| Gene Common Name(s) | ART2.2; Ag-F; Art2; Art2a; LY2; Ly-2; Ly92b; MGC116041; PtaA; RT6.1; RT6.2; Rt-6; Rt6; Rt6-2; homolog of rat transplantable antigen gene RT6; rat homolog Rt6, locus 2; | ||
| General Note | The targeting vector was electroporated into J1 ES cells carrying Art2atm1Fkn. | ||
| Molecular Note | The coding region was disrupted by a hygromycin selection cassette inserted by homologous recombination. This construct was used to transfect mice in which the Art2atm1Fkn allele had already been created Transcript was undetected in homozygousmutant mice by RT-PCR analysis of T cells isolated from lymph nodes. FACS analysis of thymocytes and lymphocytes indicated a lack of protein expression on the cell surface. [MGI Ref ID J:79607] | ||
| Allele Symbol | Cd38tm1Lnd | ||
| Allele Name | targeted mutation 1, Frances E Lund | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | CD38-; CD38null; | ||
| Mutation Made By | Debra Cockayne, Roche Bioscience | ||
| Strain of Origin | 129P2/OlaHsd | ||
| ES Cell Line Name | E14.1 | ||
| ES Cell Line Strain | 129P2/OlaHsd | ||
| Gene Symbol and Name | Cd38, CD38 antigen | ||
| Chromosome | 5 | ||
| Gene Common Name(s) | CD38 antigen, related sequence 1; Cd38-rs1; T10; | ||
| Molecular Note | A neomycin selection cassette replaced a genomic fragment containing exons 2 and 3, which encode the putative active site of the encoded protein. Homozygous mice lacked transcripts derived from this allele (data not shown). Flow cytometry analysis on splenocytes derived from homozygous mice confirmed that no detectable protein was expressed on the cell surface. [MGI Ref ID J:49170] | ||
Genotyping Protocols
Cd38tm1Ldn, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Chen J; Chen YG; Reifsnyder PC; Schott WH; Lee CH; Osborne M; Scheuplein F; Haag F; Koch-Nolte F; Serreze DV; Leiter EH. 2006. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol 176(8):4590-9. [PubMed: 16585549] [MGI Ref ID J:108097]
Chen YG; Chen J; Osborne MA; Chapman HD; Besra GS; Porcelli SA; Leiter EH; Wilson SB; Serreze DV. 2006. CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice. J Immunol 177(5):2939-47. [PubMed: 16920929] [MGI Ref ID J:112615]
Art2atm1Fkn relatedArt2btm1Fkn relatedKawamura H; Aswad F; Minagawa M; Govindarajan S; Dennert G. 2006. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J Immunol 176(4):2152-60. [PubMed: 16455971] [MGI Ref ID J:129123]
Krebs C; Adriouch S; Braasch F; Koestner W; Leiter EH; Seman M; Lund FE; Oppenheimer N; Haag F; Koch-Nolte F. 2005. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J Immunol 174(6):3298-305. [PubMed: 15749861] [MGI Ref ID J:97699]
Ohlrogge W; Haag F; Lohler J; Seman M; Littman DR; Killeen N; Koch-Nolte F. 2002. Generation and characterization of ecto-ADP-ribosyltransferase ART2.1/ART2.2-deficient mice. Mol Cell Biol 22(21):7535-42. [PubMed: 12370300] [MGI Ref ID J:79607]
Cd38tm1Lnd relatedHeiss K; Janner N; Mahnss B; Schumacher V; Koch-Nolte F; Haag F; Mittrucker HW. 2008. High sensitivity of intestinal CD8+ T cells to nucleotides indicates P2X7 as a regulator for intestinal T cell responses. J Immunol 181(6):3861-9. [PubMed: 18768840] [MGI Ref ID J:139109]
Kawamura H; Aswad F; Minagawa M; Govindarajan S; Dennert G. 2006. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J Immunol 176(4):2152-60. [PubMed: 16455971] [MGI Ref ID J:129123]
Krebs C; Adriouch S; Braasch F; Koestner W; Leiter EH; Seman M; Lund FE; Oppenheimer N; Haag F; Koch-Nolte F. 2005. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J Immunol 174(6):3298-305. [PubMed: 15749861] [MGI Ref ID J:97699]
Ohlrogge W; Haag F; Lohler J; Seman M; Littman DR; Killeen N; Koch-Nolte F. 2002. Generation and characterization of ecto-ADP-ribosyltransferase ART2.1/ART2.2-deficient mice. Mol Cell Biol 22(21):7535-42. [PubMed: 12370300] [MGI Ref ID J:79607]
Aksoy P; White TA; Thompson M; Chini EN. 2006. Regulation of intracellular levels of NAD: A novel role for CD38. Biochem Biophys Res Commun 345(4):1386-92. [PubMed: 16730329] [MGI Ref ID J:109655]
Barbosa MT; Soares SM; Novak CM; Sinclair D; Levine JA; Aksoy P; Chini EN. 2007. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J 21(13):3629-39. [PubMed: 17585054] [MGI Ref ID J:134922]
Bergthorsdottir S; Gallagher A; Jainandunsing S; Cockayne D; Sutton J; Leanderson T; Gray D. 2001. Signals that initiate somatic hypermutation of B cells in vitro. J Immunol 166(4):2228-34. [PubMed: 11160276] [MGI Ref ID J:127146]
Ceni C; Pochon N; Villaz M; Muller-Steffner H; Schuber F; Baratier J; De Waard M; Ronjat M; Moutin MJ. 2006. The CD38-independent ADP-ribosyl cyclase from mouse brain synaptosomes: a comparative study of neonate and adult brain. Biochem J 395(2):417-26. [PubMed: 16411897] [MGI Ref ID J:115899]
Cockayne DA; Muchamuel T; Grimaldi JC; Muller-Steffner H; Randall TD; Lund FE; Murray R; Schuber F; Howard MC. 1998. Mice deficient for the ecto-nicotinamide adenine dinucleotide Blood 92(4):1324-33. [PubMed: 9694721] [MGI Ref ID J:49170]
Deshpande DA; White TA; Guedes AG; Milla C; Walseth TF; Lund FE; Kannan MS. 2005. Altered airway responsiveness in CD38-deficient mice. Am J Respir Cell Mol Biol 32(2):149-56. [PubMed: 15557017] [MGI Ref ID J:107616]
Gul R; Kim SY; Park KH; Kim BJ; Kim SJ; Im MJ; Kim UH. 2008. A novel signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 295(1):H77-88. [PubMed: 18456728] [MGI Ref ID J:138213]
Iqbal J; Zaidi M. 2006. TNF regulates cellular NAD+ metabolism in primary macrophages. Biochem Biophys Res Commun 342(4):1312-8. [PubMed: 16516847] [MGI Ref ID J:107073]
Johnson JD; Ford EL; Bernal-Mizrachi E; Kusser KL; Luciani DS; Han Z; Tran H; Randall TD; Lund FE; Polonsky KS. 2006. Suppressed insulin signaling and increased apoptosis in CD38-null islets. Diabetes 55(10):2737-46. [PubMed: 17003338] [MGI Ref ID J:116576]
Krebs C; Adriouch S; Braasch F; Koestner W; Leiter EH; Seman M; Lund FE; Oppenheimer N; Haag F; Koch-Nolte F. 2005. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J Immunol 174(6):3298-305. [PubMed: 15749861] [MGI Ref ID J:97699]
Manjarrez-Orduno N; Moreno-Garcia ME; Fink K; Santos-Argumedo L. 2007. CD38 cross-linking enhances TLR-induced B cell proliferation but decreases IgM plasma cell differentiation. Eur J Immunol 37(2):358-67. [PubMed: 17274001] [MGI Ref ID J:117900]
Mayo L; Jacob-Hirsch J; Amariglio N; Rechavi G; Moutin MJ; Lund FE; Stein R. 2008. Dual role of CD38 in microglial activation and activation-induced cell death. J Immunol 181(1):92-103. [PubMed: 18566373] [MGI Ref ID J:137179]
Partida-Sanchez S; Cockayne DA; Monard S; Jacobson EL; Oppenheimer N; Garvy B; Kusser K; Goodrich S; Howard M; Harmsen A; Randall TD; Lund FE. 2001. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 7(11):1209-16. [PubMed: 11689885] [MGI Ref ID J:126192]
Partida-Sanchez S; Goodrich S; Kusser K; Oppenheimer N; Randall TD; Lund FE. 2004. Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 20(3):279-91. [PubMed: 15030772] [MGI Ref ID J:89773]
Rodriguez-Alba JC; Moreno-Garcia ME; Sandoval-Montes C; Rosales-Garcia VH; Santos-Argumedo L. 2008. CD38 induces differentiation of immature transitional 2 B lymphocytes in the spleen. Blood 111(7):3644-52. [PubMed: 18223169] [MGI Ref ID J:133536]
Shi G; Partida-Sanchez S; Misra RS; Tighe M; Borchers MT; Lee JJ; Simon MI; Lund FE. 2007. Identification of an alternative G{alpha}q-dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes. J Exp Med 204(11):2705-18. [PubMed: 17938235] [MGI Ref ID J:126146]
Sun L; Iqbal J; Dolgilevich S; Yuen T; Wu XB; Moonga BS; Adebanjo OA; Bevis PJ; Lund F; Huang CL; Blair HC; Abe E; Zaidi M. 2003. Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption. FASEB J 17(3):369-75. [PubMed: 12631576] [MGI Ref ID J:82191]
Young GS; Choleris E; Lund FE; Kirkland JB. 2006. Decreased cADPR and increased NAD+ in the Cd38-/- mouse. Biochem Biophys Res Commun 346(1):188-92. [PubMed: 16750163] [MGI Ref ID J:110441]
Currently there no information available for this strain. This may be due to the supply level of this strain.
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00 Cryopreserved Embryos Fee $1600.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00 Cryopreserved Embryos Fee $2080.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| 001976 NOD/ShiLtJ | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.